Visit https://www.peervoice.com/FPN860 to view the entire programme with slides. After completing “Thanai Pongdee, MD - From Diagnosis to Treatment Escalation: Improving Outcomes Across the Patient Journey in Indolent Systemic Mastocytosis”, participants will be able to: Differentiate symptoms of indolent systemic mastocytosis (ISM) from other conditions with cutaneous manifestations; Implement evidence-based practices in the initial diagnosis and management of ISM; Utilize recommended clinical tools for the evaluation of symptoms and quality of life (QoL) in patients with ISM; and Identify patients with ISM who would benefit from escalation from symptomatic-directed therapies to disease-modifying therapies (such as selective KIT inhibitors).

Visit https://www.peervoice.com/BVP860 to view the entire programme with slides. After completing “Howard Trachtman, MD - Pioneering Progress In Focal Segmental Glomerulosclerosis: Time is Ticking To Save The Nephron”, participants will be able to: Identify the current challenges in the diagnosis and management of focal segmental glomerulosclerosis (FSGS); Recognise genetic and socio-environmental factors that contribute to the disproportionate burden of FSGS and end stage kidney disease in Black communities; Describe the pathophysiology of FSGS, including the role of endothelin-1 and angiotensin II in glomerular injury; and Appraise recent data from trials examining the safety and efficacy of emerging therapies in FSGS.

Visit https://www.peervoice.com/MZY860 to view the entire programme with slides. After completing “Saiju Jacob, MD, DPhil, FRCP, FAAN - The Value of Disease Control in gMG: The Latest Data Evaluating Patient Needs and Treatment Outcomes as They Emerge From Helsinki”, participants will be able to:

Visit https://www.peervoice.com/ZCC860 to view the entire programme with slides. After completing “Anna Maria Geretti, MD, PhD - Understanding an Individual’s Readiness for Long-Acting Injectable Therapy”, participants will be able to: Describe the eligibility criteria and patient factors that impact whether long-acting injectable antiretroviral therapy (LAI-ART) is a treatment option for an individual with HIV; Explain key information that individuals with HIV need to know about the potential benefits and limitations of LAI-ART in order for them to be able to make informed decisions on their LAI-ART readiness; and Use clinical factors and patient characteristics to evaluate an individual’s eligibility and readiness for LAI-ART.

Visit https://www.peervoice.com/SDS860 to view the entire programme with slides. After completing “Thomas Dörner, MD - B-Cell Depletion for Autoimmune Rheumatic Diseases: Expert Perspectives of This Mechanistic Therapeutic Approach in Clinical Context”, participants will be able to: Explain the impact of suboptimal treatment of autoimmune rheumatic diseases on patient outcomes; Discuss the mechanistic role of B cells in the pathophysiology of autoimmune rheumatic diseases; Explain why—despite suboptimal results with established B-cell–targeting therapies in autoimmune rheumatic diseases such as Sjögren’s disease, systemic lupus erythematosus (SLE), and lupus nephritis—B-cell–targeting still holds therapeutic promise; and Identify B-cell–targeting therapies currently being investigated for autoimmune rheumatic diseases and their methods for achieving B-cell depletion.

Visit https://www.peervoice.com/WWE860 to view the entire programme with slides. After completing “Nicholas J. Silvestri, MD, FAAN - From Established to Emerging Therapies: Expert Perspectives on the Latest Evidence Base on FcRn Inhibitors for gMG”, participants will be able to:

Visit https://www.peervoice.com/DSN860 to view the entire programme with slides. After completing “James F. Howard Jr, MD - Beyond FcRn and Complement Inhibitors: Why We Need Novel Treatment Options for Generalized Myasthenia Gravis”, participants will be able to: Explain how the immunological processes underpinning the pathophysiology of generalised myasthenia gravis (gMG) are targeted by the novel mechanisms of action of emerging therapies; Discuss key characteristics of currently available targeted therapies for gMG with particular reference to potential benefits and limitations; and Evaluate how specific patient factors can impact individualised treatment plans.

Visit https://www.peervoice.com/JJU860 to view the entire programme with slides. After completing “Mariana Castells, MD, PhD - Rare But Highly Significant: Best Practices in Recognizing and Diagnosing Systemic Mastocytosis”, participants will be able to: Recognize the prevalence, symptoms, and outcomes associated with systemic mastocytosis (SM); Identify patients who should be referred for diagnostic tests to investigate suspected SM; and Identify diagnostic tests used to investigate and identify cases of SM.

Visit https://www.peervoice.com/HTH860 to view the entire programme with slides. After completing “Pushpa Narayanaswami, MD, FAAN - Cutting Through the Congress Cacophony on Generalised Myasthenia Gravis: Expert Honing of the Latest Data”, participants will be able to: Analyse the evidence and characteristics of next-generation and new formulations of therapies for generalised myasthenia gravis (gMG) and how they differentiate within class; Translate emerging clinical data for approved targeted therapies in the context of current clinical practice for the management of patients with gMG; and Evaluate data on emerging novel therapies for gMG.

Visit https://www.peervoice.com/BQX860 to view the entire programme with slides. After completing “Onyema Ogbuagu, MD, FACP, FIDSA - Multidrug-Resistant HIV: Evaluating HIV Treatment Strategies as Options Narrow”, participants will be able to: Identify patient and disease characteristics that can impact decisions on next treatment steps for individuals living with multidrug-resistant HIV (MDR HIV); and Propose individualised evidence-based treatment strategies to optimise outcomes of individuals living with MDR HIV.

Visit https://www.peervoice.com/JGN860 to view the entire programme with slides. After completing “Stephen Jolles, MRCP, FRCPath, PhD - The Many Faces of Primary Immunodeficiencies: Exploring the Plethora of Possibilities Impacting Patient-Integrated Care”, participants will be able to: Recognise the need for an early and accurate diagnosis of primary immunodeficiency diseases (PID); Differentiate between the clinical presentation of infectious and non-infectious manifestations of PID; Use patient factors, clinical features and laboratory testing to facilitate an effective approach to a timely and accurate diagnosis of PID; and Propose an individualised approach to patient-integrated care of PID that optimises therapeutic and management needs of patients and clinicians.

Visit https://www.peervoice.com/VWE860 to view the entire programme with slides. After completing “Janet Pope, MD, MPH, FRCPC - Understanding the Relevance of Rheumatoid Factor Titers in Rheumatoid Arthritis: From Prognosis to Treatment”, participants will be able to: Recognize rheumatoid factor (RF) as a poor prognostic marker in rheumatoid arthritis (RA); Explain how RF may impact serum drug levels and response to biologic therapy; and Evaluate the latest data with biologic therapies showcasing clinical outcomes according to RF titers.

Visit https://www.peervoice.com/NXY860 to view the entire programme with slides. After completing “Frank Siebenhaar, PD / Vito Sabato, MD, PhD - Optimising Outcomes in Indolent Systemic Mastocytosis: A Comprehensive Review of Best Practices Across the Patient Journey”, participants will be able to: Differentiate the symptoms, causes and outcomes associated with childhood-onset and adult-onset presentations of mastocytosis; Utilise recommended clinical tools for the evaluation of symptoms and quality of life (QoL) in patients with indolent systemic mastocytosis (ISM); and Implement evidence-based best practices in the diagnosis, monitoring and management of ISM.

Visit https://www.peervoice.com/VZX860 to view the entire programme with slides. After completing “Sharon Walmsley, MD - If the Drugs Are Working, Why Switch HIV Treatment in People Who Are Virologically Suppressed?”, participants will be able to: Explain the rationale for switching antiretroviral therapy (ART) regimens in people with virologically suppressed HIV; Assess the clinical and patient-reported outcomes (PRO) data for HIV switch regimens for people with virologically suppressed HIV; and Based on clinical trial populations, evaluate eligibility criteria of people with virologically suppressed HIV for an ART switch.

Visit https://www.peervoice.com/FDX860 to view the entire programme with slides. After completing “Jane Anderson, FRCP, PhD - Health-Related Quality of Life: What Works Best for People Living With HIV?”, participants will be able to: Summarise the rationale for integrating patient-reported outcomes (PRO) instruments into routine clinical practice when caring for people living with HIV; Explain how PRO measures (PROM) can be effectively integrated into routine clinical practice; Identify how PRO can inform HIV treatment plans that optimise outcomes; and Propose practical approaches to overcoming communication challenges when exploring quality of life (QoL) alongside clinical outcomes with people living with HIV.

Visit https://www.peervoice.com/YBG860 to view the entire programme with slides. After completing “Jan Dutz, MD, FRCPC - Clinical Updates on Targeting IL-17 in Rheumatic Diseases: Striking at the Heart of Inflammatory Processes in PsA and axSpA”, participants will be able to: Discuss unmet needs in the management of patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA); Evaluate the evidence with new targeted therapies for PsA and axSpA; and Outline the clinical implications with new therapies for the management of patients with PsA and axSpA.

Visit https://www.peervoice.com/AFQ860 to view the entire programme with slides. After completing “Xenofon Baraliakos, MD, PhD / Philip Helliwell, MD, PhD - Can the Standard of Care Be Elevated in Spondyloarthropathies? Key Learnings From Rheumacensus Initiatives in PsA and axSpA”, participants will be able to: Describe the rationale, design, and key areas of focus of the Rheumacensus programmes in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA); Identify the overarching calls to action needed to implement a paradigm shift designed to elevate health outcomes in patients with PsA and axSpA, as defined by the Rheumacensus Consensus Council; and Propose practical steps to elevate the standard of care for patients with PsA and axSpA based upon results of the Rheumacensus Initiatives.

Visit https://www.peervoice.com/HUM860 to view the entire programme with slides. After completing “Milan J. Anadkat, MD - Supporting Patient-Centered Care in Generalized Pustular Psoriasis: Communications Strategies to Improve Shared Decision-Making”, participants will be able to: Describe key information regarding the disease process and course following the diagnosis of generalized pustular psoriasis (GPP); Address common concerns raised by patients with GPP; and Develop appropriate treatment plans with patients for the management of GPP.

Visit https://www.peervoice.com/BBT860 to view the entire programme with slides. After completing “Xavier Montalban, MD, PhD - Multiple Sclerosis and Bruton’s Tyrosine Kinase Inhibitors: Therapeutic Potential Beyond Biologics?”, participants will be able to: Describe the benefits and limitations of current disease-modifying strategies in multiple sclerosis (MS); Discuss the role of Bruton’s tyrosine kinase (BTK) in the pathological processes associated with disease progression in patients with MS; and Use clinical data to evaluate on-target and off-target effects of emerging BTK inhibitors for patients with MS in the context of current clinical management.

Visit https://www.peervoice.com/DPR860 to view the entire programme with slides. After completing “Martin van Hagen, MD, PhD - Patients Receiving Immunoglobulin Therapy: Emerging Technology for Patient-Integrated Care”, participants will be able to: Discuss how technology has been used to optimise care of chronic diseases; Recognise the needs for simplifying the management of immunoglobulin therapy using device and digital technologies; and Identify technologies that are in development to support patient-integrated care for those requiring immunoglobulin therapy and key considerations for their implementation.